enGene (ENGN) Competitors $4.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.07 +0.07 (+1.75%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, CDMO, and RCUSShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. enGene vs. Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Syndax Pharmaceuticals (NASDAQ:SNDX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Which has better valuation and earnings, SNDX or ENGN? enGene has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04enGeneN/AN/A-$55.14M-$1.52-2.63 Which has more volatility & risk, SNDX or ENGN? Syndax Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Do insiders and institutionals hold more shares of SNDX or ENGN? 64.2% of enGene shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate SNDX or ENGN? Syndax Pharmaceuticals currently has a consensus price target of $36.20, indicating a potential upside of 219.51%. enGene has a consensus price target of $24.13, indicating a potential upside of 503.13%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90enGene 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to SNDX or ENGN? In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than enGene. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 4 mentions for enGene. Syndax Pharmaceuticals' average media sentiment score of 1.01 beat enGene's score of 0.61 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is SNDX or ENGN more profitable? enGene's return on equity of -16.69% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% enGene N/A -16.69%-14.27% Does the MarketBeat Community prefer SNDX or ENGN? Syndax Pharmaceuticals received 372 more outperform votes than enGene when rated by MarketBeat users. However, 95.00% of users gave enGene an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% enGeneOutperform Votes1995.00% Underperform Votes15.00% SummaryenGene beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Remove Ads Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.91M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-6.9031.0021.7317.81Price / SalesN/A441.15379.1494.58Price / CashN/A168.6838.1534.64Price / Book0.653.476.464.00Net Income-$55.14M-$72.06M$3.20B$247.23M7 Day Performance-2.91%9.33%6.54%7.26%1 Month Performance-25.93%-16.97%-8.55%-6.26%1 Year Performance-74.67%-29.10%10.33%-0.18% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.0741 of 5 stars$4.00flat$24.13+503.1%-74.0%$203.91MN/A-6.9031SNDXSyndax Pharmaceuticals3.4858 of 5 stars$11.01-2.1%$36.20+228.8%-48.3%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1802 of 5 stars$5.80-3.8%$22.60+289.7%+3.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.1648 of 5 stars$27.38-2.7%$43.60+59.2%-25.1%$879.77M$631.45M11.80210News CoveragePositive NewsGap DownELVNEnliven Therapeutics2.5509 of 5 stars$17.87-4.4%$38.75+116.8%-18.5%$875.70MN/A-9.4150News CoverageDYNDyne Therapeutics3.73 of 5 stars$7.49-9.5%$47.46+533.7%-71.1%$847.28MN/A-2.10100Positive NewsGPCRStructure Therapeutics2.5699 of 5 stars$14.31-5.4%$81.29+468.0%-51.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5806 of 5 stars$5.49-4.9%$27.56+401.9%-39.7%$801.45MN/A-1.8940Short Interest ↑News CoverageGap DownHigh Trading VolumeCMRXChimerix2.9137 of 5 stars$8.52-0.1%$8.53+0.2%+788.9%$799.21M$212,000.00-9.0690CDMOAvid Bioservices0.7921 of 5 stars$12.50+0.1%$12.25-2.0%+85.4%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4548 of 5 stars$7.28+5.9%$30.25+315.8%-53.7%$764.88M$258M-2.31500High Trading Volume Remove Ads Related Companies and Tools Related Companies SNDX Competitors WVE Competitors COLL Competitors ELVN Competitors DYN Competitors GPCR Competitors ETNB Competitors CMRX Competitors CDMO Competitors RCUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENGN Stock Free ENGN Stock Alerts